TSX:ONC - Toronto Stock Exchange - CA6823108759 - Common Stock - Currency: CAD
TSX:ONC (2/21/2025, 7:00:00 PM)
1.03
-0.02 (-1.9%)
The current stock price of ONC.CA is 1.03 CAD. In the past month the price decreased by -11.97%. In the past year, price decreased by -23.7%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 261.54M | ||
EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 188.23M | ||
EDT.CA | SPECTRAL MEDICAL INC | N/A | 185.09M | ||
TH.CA | THERATECHNOLOGIES INC | N/A | 121.39M | ||
MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 89.95M | ||
MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 78.27M | ||
COV.CA | COVALON TECHNOLOGIES LTD | 25.45 | 76.72M | ||
MBX.CA | MICROBIX BIOSYSTEMS INC | 48.5 | 65.22M | ||
MDCX.CA | MEDICUS PHARMA LTD | N/A | 61.74M | ||
SVA.CA | SERNOVA BIOTHERAPEUTICS INC | N/A | 52.45M | ||
HBP.CA | HELIX BIOPHARMA CORP | N/A | 51.96M | ||
HEM.CA | HEMOSTEMIX INC | N/A | 25.50M |
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta. The company went IPO on 2000-06-01. The firm is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
ONCOLYTICS BIOTECH INC
804, 322 - 11 Avenue Sw, Calgary Alberta Canada T2n 1X7
Calgary ALBERTA T2N 1X7 CA
CEO: Matthew C. Coffey
Employees: 29
Company Website: https://www.oncolyticsbiotech.com/
Investor Relations: http://www.oncolyticsbiotech.com/investor-centre/investor-overview/
Phone: 14036707377
The current stock price of ONC.CA is 1.03 CAD. The price decreased by -1.9% in the last trading session.
The exchange symbol of ONCOLYTICS BIOTECH INC is ONC and it is listed on the Toronto Stock Exchange exchange.
ONC.CA stock is listed on the Toronto Stock Exchange exchange.
9 analysts have analysed ONC.CA and the average price target is 6.53 CAD. This implies a price increase of 533.79% is expected in the next year compared to the current price of 1.03. Check the ONCOLYTICS BIOTECH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ONCOLYTICS BIOTECH INC (ONC.CA) has a market capitalization of 82.42M CAD. This makes ONC.CA a Micro Cap stock.
ONCOLYTICS BIOTECH INC (ONC.CA) currently has 29 employees.
ONCOLYTICS BIOTECH INC (ONC.CA) has a resistance level at 1.07. Check the full technical report for a detailed analysis of ONC.CA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ONC.CA does not pay a dividend.
ONCOLYTICS BIOTECH INC (ONC.CA) will report earnings on 2025-03-06, after the market close.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 80% to ONC.CA. The Buy consensus is the average rating of analysts ratings from 9 analysts.